Application of temperature-sensitive liquid embolic agent loaded with oxaliplatin in the TACE procedure for rabbit VX2 gastric cancer

被引:1
作者
Li, Yahua [1 ]
Ge, Xiaoyong [1 ]
Li, Zongming [1 ]
Zhou, Zihe [1 ]
Wu, Kunpeng [1 ]
Li, Yifan [1 ]
Ji, Tengfei [2 ]
Wang, Changran [2 ]
Guo, Kefeng [3 ]
Ren, Jianzhuang [1 ]
Han, Xinwei [1 ,4 ,5 ]
Ren, Kewei [1 ,6 ]
机构
[1] Zhengzhou Univ, Dept Intervent Radiol, Affiliated Hosp 1, Zhengzhou 450052, Peoples R China
[2] Zhoukou Chinese Med Hosp, Dept Peripheral Vasc, Zhoukou 466000, Peoples R China
[3] Yellow River Sanmenxia Hosp, Dept Oncol, Sanmenxia 472000, Peoples R China
[4] Intervent Treatment & Clin Res Ctr Henan Prov, Zhengzhou 450052, Peoples R China
[5] Zhengzhou Univ, Intervent Inst, Zhengzhou 450052, Peoples R China
[6] Engn Technol Res Ctr Minimally Invas, Intervent Tumors Henan Prov, Zhengzhou 450052, Henan, Peoples R China
关键词
Temperature-sensitive liquid embolic agent; Oxaliplatin; Transcatheter arterial chemoembolization; VX2 gastric cancer; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; DRUG-DELIVERY SYSTEMS; HYDROGELS; EXPRESSION; EFFICACY; NANOGEL; VEGF;
D O I
10.1007/s13346-023-01425-5
中图分类号
TH7 [仪器、仪表];
学科分类号
0804 ; 080401 ; 081102 ;
摘要
As a promising drug delivery system, the temperature-sensitive liquid embolic agent (TempSLE) has yet to be reported in animal experiments in treating gastric cancer. We observed and compared computed tomography (CT) imaging changes, tumor volume, HE staining, and immunohistochemistry after transcatheter arterial chemoembolization (TACE) treatment in rabbit VX2 gastric cancer models to clarify the effectiveness of TempSLE loaded with oxaliplatin (TempSLE/Oxa) in treating gastric cancer. One milliliter TempSLE can be loaded with 20 mg oxaliplatin. The accumulative drug release rate at 30 min was 38.76%, and after 24 h, it reached more than 90%. CT examination 1 week after TACE revealed that the TempSLE/Oxa group presents unenhanced hypodense necrotic foci, the iodinated oil loaded with oxaliplatin (Ioil/Oxa) group presents shrinking tumors but still visible speckled foci of enhancement, and the normal saline (NS) group presents heterogeneous enhancement with larger tumors than before. In the postoperative autopsy of TACE, the tumor volumes of TempSLE/Oxa, Ioil/Oxa, and NS groups were 0.15 & PLUSMN; 0.06 cm3, 0.37 & PLUSMN; 0.11 cm3, and 1.19 & PLUSMN; 0.16 cm3, respectively, all of which were statistically different. The positive vascular endothelial growth factor (VEGF) and proliferating cell nuclear antigen (PCNA) expression percentages in the TempSLE/Oxa, Ioil/Oxa, and NS groups were statistically different and lowest in the TempSLE/Oxa group. In conclusion, the TempSLE can load a high dose of oxaliplatin to meet the demand of clinical applications. TempSLE/Oxa could effectively inhibit tumor cell proliferation and angiogenesis. This study provides experimental evidence for the further clinical application of the TempSLE/Oxa.
引用
收藏
页码:705 / 717
页数:13
相关论文
共 37 条
  • [1] Gastric Cancer, Version 2.2022
    Ajani, Jaffer A.
    D'Amico, Thomas A.
    Bentrem, David J.
    Chao, Joseph
    Cooke, David
    Corvera, Carlos
    Das, Prajnan
    Enzinger, Peter C.
    Enzler, Thomas
    Fanta, Paul
    Farjah, Farhood
    Gerdes, Hans
    Gibson, Michael K.
    Hochwald, Steven
    Hofstetter, Wayne L.
    Ilson, David H.
    Keswani, Rajesh N.
    Kim, Sunnie
    Kleinberg, Lawrence R.
    Klempner, Samuel J.
    Lacy, Jill
    Ly, Quan P.
    Matkowskyj, Kristina A.
    McNamara, Michael
    Mulcahy, Mary F.
    Outlaw, Darryl
    Park, Haeseong
    Perry, Kyle A.
    Pimiento, Jose
    Poultsides, George A.
    Reznik, Scott
    Roses, Robert E.
    Strong, Vivian E.
    Su, Stacey
    Wang, Hanlin L.
    Wiesner, Georgia
    Willett, Christopher G.
    Yakoub, Danny
    Yoon, Harry
    McMillian, Nicole
    Pluchino, Lenora A.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (02): : 167 - 192
  • [2] A detailed insight of the tumor targeting using nanocarrier drug delivery system
    Batool, Sibgha
    Sohail, Saba
    Din, Fakhar Ud
    Alamri, Ali H.
    Alqahtani, Ahmad S.
    Alshahrani, Mohammad A.
    Alshehri, Mohammed A.
    Choi, Han Gon
    [J]. DRUG DELIVERY, 2023, 30 (01)
  • [3] The safety and efficacy of oxaliplatin-loaded drug-eluting beads transarterial chemoembolization for the treatment of unresectable or advanced lung cancer
    Bi, Yonghua
    Li, Fazhong
    Ren, Jianzhuang
    Han, Xinwei
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [4] Oxaliplatin Eluting CalliSpheres Microspheres for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma
    Bi, Yonghua
    Ren, Kewei
    Ren, Jianzhuang
    Ma, Ji
    Han, Xinwei
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [5] Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
    Din, Fakhar Ud
    Aman, Waqar
    Ullah, Izhar
    Qureshi, Omer Salman
    Mustapha, Omer
    Shafique, Shumaila
    Zeb, Alam
    [J]. INTERNATIONAL JOURNAL OF NANOMEDICINE, 2017, 12 : 7291 - 7309
  • [6] Irinotecan-loaded double-reversible thermogel with improved antitumor efficacy without initial burst effect and toxicity for intramuscular administration
    Din, Fakhar Ud
    Kim, Dong Wuk
    Choi, Ju Yeon
    Thapa, Raj Kumar
    Mustapha, Omer
    Kim, Dong Shik
    Oh, Yu-Kyoung
    Ku, Sae Kwang
    Youn, Yu Seok
    Oh, Kyung Taek
    Yong, Chul Soon
    Kim, Jong Oh
    Choi, Han-Gon
    [J]. ACTA BIOMATERIALIA, 2017, 54 : 239 - 248
  • [7] Irinotecan-encapsulated double-reverse thermosensitive nanocarrier system for rectal administration
    Din, Fakhar ud
    Choi, Ju Yeon
    Kim, Dong Wuk
    Mustapha, Omer
    Kim, Dong Shik
    Thapa, Raj Kumar
    Ku, Sae Kwang
    Youn, Yu Seok
    Oh, Kyung Taek
    Yong, Chul Soon
    Kim, Jong Oh
    Choi, Han-Gon
    [J]. DRUG DELIVERY, 2017, 24 (01) : 502 - 510
  • [8] Transcatheter arterial chemoembolization in hepatocellular carcinoma
    Farinati, F
    Rinaldi, M
    Gianni, S
    Marin, G
    [J]. HEPATOLOGY, 1998, 28 (05) : 1441 - 1442
  • [9] Fu JD, 2019, EUR REV MED PHARMACO, V23, P155, DOI 10.26355/eurrev_201901_16759
  • [10] Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma
    Golfieri, R.
    Giampalma, E.
    Renzulli, M.
    Cioni, R.
    Bargellini, I.
    Bartolozzi, C.
    Breatta, A. D.
    Gandini, G.
    Nani, R.
    Gasparini, D.
    Cucchetti, A.
    Bolondi, L.
    Trevisani, F.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 111 (02) : 255 - 264